Quick Takeaways: Why It Matters? By expanding Cancer Dx and inVue Dx, IDEXX tightens its grip on veterinary oncology workflows, nudging clinics toward proactive, panel-based cancer screening rather than reactive testing. Bundling mast cell detection at no extra c...
Quick Takeaways: Why It Matters? The DR50 Plus strengthens IDEXX’s imaging ecosystem, giving clinics a premium option that combines lower dose with sharper, AI-optimized images. Dose reduction and fewer retakes can improve staff and patient safety, while tighter ...
Quick Takeaways: Why It Matters? The Bioguard agreement deepens KVP SafePath’s diagnostics pipeline with access to a broad reagent/IP library and a faster path to USDA‑licensed 4DX/3DX panels, positioning the company to enter a >$500 million North America...
Quick Takeaways: Why It Matters? With both TAS and RXE accepted, Loyal moves significantly closer to commercializing the first true longevity drug in veterinary medicine, turning canine lifespan extension into a near-term, rather than speculative, market. If LOY-002 reache...
Quick Takeaways: Why It Matters? The collaboration validates structural surfaceomics as a serious next-gen discovery tool in animal health, not just a niche academic technology. If it yields novel, conformation-specific targets, it could pave ...
Quick Takeaways: Why It Matters? A-DHA-PT gives veterinary neurologists a standardized, high‑dose DHA option developed under academic supervision, potentially making nutritional add‑on therapy a more routine consideration in dogs with idiopathic epilepsy where pharmacologic con...
Dechra Secures FDA Approval for Zygolide (Pergolide) in Equine Pituitary Pars Intermedia Dysfunction
Quick Takeaways: Why It Matters? Zygolide gives vets and owners a lower-cost, FDA-approved alternative for managing PPID, which should improve treatment uptake in senior horses. The focus on flexible dosing and palatability makes long-term therapy more practical in th...
